南财智讯1月4日电，春立医疗发布2025年前三季度权益分派实施公告，公司拟向全体股东每股派发现金 红利0.21元（含税），股权登记日为2026年1月8日，现金红利发放日为2026年1月9日。本次权益分派实 际利润分配总额为8026.02万元（含税）。公司回购专用证券账户中的股份不参与本次权益分派。 ...

公司公告汇总 截至2025年12月26日收盘，春立医疗（688236）报收于23.71元，较上周的24.84元下跌4.55%。本周， 春立医疗12月22日盘中最高价报24.99元。12月24日盘中最低价报23.53元。春立医疗当前最新总市值 87.76亿元，在医疗器械板块市值排名40/127，在两市A股市值排名2144/5181。 本周关注点 公司公告汇总：春立医疗2025年第二次临时股东大会审议通过取消监事会及修订多项治理制度的 议案。 北京市万商天勤律师事务所出具法律意见书，确认本次股东大会的召集、召开程序、出席会议人员资 格、召集人资格、表决程序及表决结果均符合相关法律法规及公司章程规定，会议决议合法有效。本次 股东大会审议通过了关于取消监事会并修订《公司章程》、修订《股东会议事规则》和《董事会议事规 则》的议案，各项议案均已获得出席股东所持表决权的三分之二以上通过。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 北京市春立正达医疗器械股份有限公司于2025年12月29日召开2025年第二次临时股东大会，会议由董事 会召集， ...

Group 1 - The core investment theme for the pharmaceutical industry in 2025 is the overseas expansion of innovative drugs, which is expected to yield excess returns compared to the broader pharmaceutical sector and the CSI 300 index [2][21] - The innovative drug index has shown a significant increase, outperforming the pharmaceutical biological index by 37.48 percentage points, with a year-to-date increase of 65.99% [21] - Major transactions in the ADC and dual antibody fields are anticipated to continue, while there is a need to avoid repetitive competition in areas like small nucleic acids and focus on unmet clinical needs [3][4] Group 2 - The report emphasizes the importance of overseas markets for both innovative drugs and medical devices, suggesting that companies should seek growth opportunities beyond domestic market saturation [4][5] - The Chinese pharmaceutical industry is gradually becoming a global innovation center, with significant advancements in dual antibodies and ADCs, while also making strides in emerging fields like small nucleic acids and inhalation formulations [5][6] - The report highlights that the overseas authorization revenue has become a crucial funding source for innovative drug development, with a total upfront payment of $4.551 billion in the first three quarters of 2025 [29][32] Group 3 - The medical device sector is experiencing a shift towards overseas expansion, with a focus on high-value consumables and IVD products, as Chinese companies enhance their market share [7][55] - The export growth of high-value consumables is significant, with a recorded increase of 10.75% in the first half of 2025, particularly in the North American and European markets [57][66] - The report notes that the certification and market establishment processes for high-value consumables are long-term investments, requiring compliance with stringent regulations in the EU and the US [60][61] Group 4 - The recovery of financing in the domestic innovative drug sector has been robust, with a total of 324 financing events amounting to $5.51 billion in the first three quarters of 2025, marking a 67.6% increase year-on-year [70][72] - The CXO industry is experiencing varied recovery rhythms across different segments, with some areas like CDMO seeing order growth due to overseas financing recovery [74]

Core Viewpoint - Spring Medical is a leading domestic orthopedic medical device manufacturer, focusing on the research, production, and sales of implantable orthopedic medical devices, including joint prosthetics and spinal implants [2][5]. Company Overview - Spring Medical, established on February 12, 1998, and listed on December 30, 2021, is located in Tongzhou District, Beijing. The company specializes in implantable orthopedic medical devices [7][8]. - The main products include joint prosthetics covering hip, knee, shoulder, and elbow joints, as well as a full range of spinal implant systems [8]. Product Development - The company has developed products such as hip and knee surgical robots and medical image processing software for surgical planning, indicating its investment in smart medical technology [2][3]. - Spring Medical is in the design and inspection phase for customized porous tantalum dental implants [2]. Industry Recognition - The company has been recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, which is a prestigious title in China for small and medium enterprises that excel in niche markets and innovation [3]. Financial Performance - For the period from January to September 2025, Spring Medical achieved a revenue of 756 million yuan, representing a year-on-year growth of 48.75%, and a net profit attributable to shareholders of 192 million yuan, with a year-on-year increase of 213.21% [8]. - The company has distributed a total of 359 million yuan in dividends since its A-share listing, with 309 million yuan in the last three years [9]. Shareholder Information - As of September 30, 2025, the number of shareholders increased by 4.12% to 6,164, while the average circulating shares per person decreased by 3.95% [8]. - Notable new institutional shareholders include Hong Kong Central Clearing Limited and China Europe Economic Growth Mixed Fund A [9].

Group 1 - The core viewpoint of the article highlights the financial performance and stock activity of Chunli Medical (688236) as of December 30, 2025, showing a stock price increase and significant revenue growth [1][2]. - Chunli Medical reported a main revenue of 756 million yuan for the first three quarters of 2025, representing a year-on-year increase of 48.75% [2]. - The net profit attributable to shareholders for the same period was 192 million yuan, reflecting a substantial year-on-year increase of 213.21% [2]. - The company achieved a single-quarter main revenue of 268 million yuan in Q3 2025, which is a remarkable year-on-year increase of 109.51% [2]. - The net profit attributable to shareholders for Q3 2025 was 77.06 million yuan, showing a significant year-on-year increase of 531.12% [2]. - Chunli Medical's gross profit margin stands at 67.27%, indicating strong profitability in its operations [2]. Group 2 - The stock's trading activity on December 30, 2025, showed a net outflow of 846,000 yuan from main funds, accounting for 1.92% of the total trading volume [1]. - Retail investors contributed a net inflow of 868,800 yuan, representing 1.98% of the total trading volume on the same day [1]. - Over the past 90 days, 9 institutions have provided ratings for the stock, with 8 recommending a buy and 1 recommending an increase in holdings [2]. - The average target price set by institutions for Chunli Medical over the past 90 days is 3.18 billion yuan [2].

Core Viewpoint - Spring Medical (688236) experienced a decline of 4.05% on December 29, 2025, closing at 22.75 yuan, with a trading volume of 28,900 hands and a total transaction amount of 66.501 million yuan [1]. Group 1: Financial Performance - For the first three quarters of 2025, Spring Medical reported a main revenue of 756 million yuan, an increase of 48.75% year-on-year [3]. - The net profit attributable to shareholders reached 192 million yuan, reflecting a year-on-year increase of 213.21% [3]. - The net profit after deducting non-recurring gains and losses was 181 million yuan, up 311.07% year-on-year [3]. - In Q3 2025, the company achieved a single-quarter main revenue of 268 million yuan, a year-on-year increase of 109.51% [3]. - The single-quarter net profit attributable to shareholders was 77.0619 million yuan, up 531.12% year-on-year [3]. - The single-quarter net profit after deducting non-recurring gains and losses was 74.5186 million yuan, an increase of 439.4% year-on-year [3]. - The company's debt ratio stands at 15.65%, with investment income of 3.217 million yuan and financial expenses of -9.7234 million yuan, while the gross profit margin is 67.27% [3]. Group 2: Market Activity - On December 29, 2025, the net outflow of main funds was 12.8684 million yuan, accounting for 19.35% of the total transaction amount [1]. - Retail investors saw a net inflow of 6.5589 million yuan, representing 9.86% of the total transaction amount [1]. - The financing data indicates a financing buy of 10.6505 million yuan and a financing repayment of 3.9893 million yuan, resulting in a net financing buy of 6.6611 million yuan [2]. - The margin trading balance is reported at 40.7626 million yuan [2]. Group 3: Analyst Ratings - In the last 90 days, 9 institutions have provided ratings for Spring Medical, with 8 giving a buy rating and 1 giving an increase rating [3]. - The average target price set by institutions over the past 90 days is 31.8 yuan [3].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部份內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 北 京 市 春 立 正 達 醫 療 器 械 股 份 有 限 公 司 Beijing Chunlizhengda Medical Instruments Co., Ltd.* （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股 份 代 號：1858） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條由北京市春立 正達醫療器械股份有限公司（「本公司」）作出。 茲載列本公司在上海證券交易所網站刊登之《北京市萬商天勤律師事務所關於 北京市春立正達醫療器械股份有限公司2025年第二次臨時股東大會的法律意見 書》，僅供參閱。 承董事會命 北京市春立正達醫療器械股份有限公司 董事長 史文玲 中國北京，2025年12月29日 截至本公告日期，本公司執行董事為史文玲女士、史春寶先生、岳術俊女士及解鳳寶先生； 本公司非執行董事為王鑫先生；及本公司獨立非執行董事為徐 ...

北 京 市 春 立 正 達 醫 療 器 械 股 份 有 限 公 司 Beijing Chunlizhengda Medical Instruments Co., Ltd.* （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股 份 代 號：1858） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部份內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 海外監管公告 茲載列本公司在上海證券交易所網站刊登之《北京市春立正達醫療器械股份有 限公司2025年第二次臨時股東大會決議公告》，僅供參閱。 承董事會命 北京市春立正達醫療器械股份有限公司 董事長 史文玲 中國北京，2025年12月29日 截至本公告日期，本公司執行董事為史文玲女士、史春寶先生、岳術俊女士及解鳳寶先生； 本公司非執行董事為王鑫先生；及本公司獨立非執行董事為徐泓女士、翁杰先生及黃德盛先生。 * 僅供識別 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條由北京市春立 正達醫療器械股份有限公司（「本公司 ...

北京市春立正達醫療器械股份有限公司 （於中華人民共和國註冊成立之股份有限公司） 章程（H+A股） | 第一章 | 總則 | 1 | | --- | --- | --- | | 第二章 | 經營宗旨和範圍 | 3 | | 第三章 | 股份、股份轉讓和註冊資本 | 3 | | 第四章 | 減資和購回股份 | 7 | | 第五章 | 購買公司股份的財務資助 | 9 | | 第六章 | 股票和股東名冊 | 10 | | 第七章 | 股東的權利和義務 | 11 | | 第八章 | 股東會 | 17 | | 第九章 | 類別股東表決的特別程序 | 31 | | 第十章 | 董事會 | 34 | | | 第一節 董事 | 34 | | | 第二節 獨立非執行董事 | 37 | | | 第三節 董事會 | 41 | | | 第四節 董事會專門委員會 | 46 | | 第十一章 | 公司董事會秘書 | 48 | | 第十二章 | 公司總經理 | 49 | | 第十三章 | 公司董事、總經理和其他高級管理人員的資格和義務 | 51 | | 第十四章 | 財務會計制度與利潤分配 | 54 | | 第十五章 | 內部審計與會計師事務 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 北 京 市 春 立 正 達 醫 療 器 械 股 份 有 限 公 司 Beijing Chunlizhengda Medical Instruments Co., Ltd.* （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股 份 代 號：1858） 該會議由本公司董事會（「董事會」）召開，由董事長史文玲女士主持。該會議以 網絡投票及現場記名投票相結合的方式進行表決。網絡投票通過上海證券交 易所交易系統進行，由A股持有人參與。本公司核數師大信會計師事務所（特 殊普通合夥）已獲本公司委任為投票的監票人。 該會議乃遵守中國適用法律及法規、香港聯合交易所有限公司證券上市規則（「上 市規則」）及本公司章程細則的規定而召開。 – 1 – 特別股東大會投票結果公告 茲提述北京市春立正達醫療器械股份有限公司（「本公司」）日期為2025年12月9 日的通函（「該通函」）及日期為2025年1 ...